KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to $2.6 billion.

  • Edwards Lifesciences' Total Non-Current Liabilities fell 1293.54% to $2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year decrease of 1293.54%. This contributed to the annual value of $2.6 billion for FY2024, which is 1115.73% up from last year.
  • Per Edwards Lifesciences' latest filing, its Total Non-Current Liabilities stood at $2.6 billion for Q3 2025, which was down 1293.54% from $2.5 billion recorded in Q2 2025.
  • In the past 5 years, Edwards Lifesciences' Total Non-Current Liabilities ranged from a high of $3.0 billion in Q3 2024 and a low of $2.1 billion during Q3 2022
  • For the 5-year period, Edwards Lifesciences' Total Non-Current Liabilities averaged around $2.4 billion, with its median value being $2.3 billion (2023).
  • As far as peak fluctuations go, Edwards Lifesciences' Total Non-Current Liabilities soared by 2927.6% in 2024, and later crashed by 1293.54% in 2025.
  • Quarter analysis of 5 years shows Edwards Lifesciences' Total Non-Current Liabilities stood at $2.4 billion in 2021, then fell by 7.55% to $2.2 billion in 2022, then grew by 4.08% to $2.3 billion in 2023, then rose by 11.16% to $2.6 billion in 2024, then rose by 2.26% to $2.6 billion in 2025.
  • Its Total Non-Current Liabilities was $2.6 billion in Q3 2025, compared to $2.5 billion in Q2 2025 and $2.4 billion in Q1 2025.